3 Digital Health Strategies to Improve Health Plan Member Experience and other notes from around the interweb: 3 Digital Health Strategies to Improve Health Plan Member Experience. Health plans have innumerable reasons to focus on improving member experience right now. The Centers for Medicare and Medicaid Services (CMS) are heavily weighting member experience in STARS ratings and HEDIS scores. And healthcare consumers want more accessible care and support. Digital member engagement tools give health plans the opportunity to deliver a better member experience by making healthcare more convenient—which, in turn, drives satisfaction and retention. Members are also looking to get the best value for the soaring prices they’re paying for health insurance coverage. But adopting a new digital health solution can be challenging, especially when it comes to aligning goals with staff and member expectations. Building a digital engagement strategy requires buy-in from individuals across an organization. Here, we’re highlighting three strategies health plans can use to improve digital adoption and enhance the member experience. 15 biggest pharmacies by prescription revenue. Pharmacies earned a record $548 billion from prescription dispensing revenues in 2022, and 15 pharmacies account for 75 percent of that figure, according to Drug Channels. The market share from the top fifteen dipped from 2020 to 2021 and again from 2021 to 2022, according to past reports. They accounted for 78.6 percent of the market in 2020, 76.9 percent in 2021 and 75.6 percent in 2022, according to the site's past reports. The decrease from 2021 to 2022 is because of Walgreens' losses after the Prime Therapeutics deal, the report said. Five of the largest pharmaceutical companies are owned by companies that also have a pharmacy benefit manager, including CVS with Caremark, Cigna with Express Scripts, Centene with Envolve Health, Humana with CenterWell and UnitedHealth Group with Optum. Click here to see the Top 15 ranked by prescription revenue. Learn More at CPBS Now! Survey: More than Half of Payers Use Outcomes-based Contracts. About 58% of payers had at least one outcomes-based contract with a pharmacy benefit manager for prescription drugs in 2022, according to a survey published last week. In an outcomes-based contract, prescription drug reimbursement is based on the outcomes achieved for the patient. These contracts represent a shift to value-based care. Avalere Health, a healthcare business consulting firm, published the survey. The company conducted it online from February 14 to February 20 and received responses from forty-six health plans. This is the fifth year the company has conducted the survey. Of the payers that had at least one outcomes-based contract, more than 35% had more than ten outcomes-based contracts in 2022. Another 10% of payers had five to ten contracts, and a little over 10% had two to five contracts. About 15% had no contracts but were in negotiations for one or more. Less than 10% had no contracts and were not planning to take any on. In addition, the survey found that of the respondents who had at least one outcomes-based contract in 2022, the…

Medication therapy management (MTM) is a patient-centered service provided by healthcare professionals such as pharmacists, doctors, or nurses. MTM aims to optimize medication therapy for patients with chronic health conditions who take multiple medications. MTM involves a comprehensive review of a patient's medication regimen to identify and resolve medication-related problems. It also includes education and counseling to help patients manage their medications and improve their health outcomes. Incorporating medication therapy management into self-insured employer health programs is a win-win. The benefits of MTM are numerous. By optimizing medication therapy, MTM can help patients achieve better health outcomes, reduce medication-related problems, and lower healthcare costs by preventing hospitalizations and emergency room visits. Additionally, MTM can improve patient satisfaction and adherence to medication therapy. MTM services can also help healthcare providers identify and manage medication-related issues that might otherwise go unnoticed, such as drug interactions, medication side effects, or non-adherence to medication regimens. Consider an MTM program as a tool for self-insured employers to assess the efficiency of the funds they set aside to pay for the health care of their employees and dependents. Incorporating MTM into their employee health programs can be a smart investment with an expected ROI of 2x. The ROI MTM services can help reduce healthcare costs by optimizing medication therapy and preventing costly medical interventions. Additionally, by providing MTM services, self-insured employers can show that they care about their staff's health by raising morale and productivity. Learn More However, there are also challenges associated with MTM that self-insured employers should be aware of. One of the primary challenges is the cost ($.50 - $2.00 PMPM) of providing MTM services. MTM services may require additional staffing, training, and technology investments, which can be a barrier for some healthcare providers and employers. Additionally, there may be resistance from some patients who are not accustomed to working with pharmacists or other healthcare providers to manage their medication therapy. To successfully incorporate MTM into employee health programs, self-insured employers should consider the following recommendations: Start small: Begin by targeting a specific patient population or health condition and gradually expand the MTM program as resources and demand allow.Identify key partners: Collaborate with healthcare providers, such as pharmacists, doctors, and nurses, to provide MTM services to employees.Communicate the value of MTM: Educate employees on the benefits of MTM services and how they can help improve their health outcomes.Measure outcomes: Track key metrics, such as healthcare costs, hospitalizations, and medication adherence, to evaluate the effectiveness of MTM services and identify areas for improvement. In summary, MTM is a patient-centered service that can help optimize medication therapy and improve patient outcomes when incorporating medication therapy management into self-insured employer health programs. For self-insured employers, incorporating MTM into employee health programs can lead to improved health outcomes, reduced healthcare costs, and improved employee satisfaction and productivity. However, to successfully incorporate MTM into employee health programs, self-insured employers must carefully consider the costs, benefits, and challenges associated with this service and develop a strategic plan for implementation.

Biosimilars Are Mighty, Can Help Alleviate Drug Spend Cost Burden and other notes from around the interweb: Ohio attorney general sues pharmacy benefit managers, calling them gangsters. Calling them "modern gangsters," Ohio Attorney General Dave Yost on Monday accused pharmacy benefit managers of illegally driving up drug prices for patients who rely on insulin and other key medications. “Medications shouldn’t cost an arm and a leg, metaphorically or literally,” Yost said in a written statement. “Insulin is just a symptom of the problem; PBMs are the disease.” Yost filed a lawsuit in Delaware County Common Pleas Court against Express Scripts, Prime Therapeutics, Ascent, Humana Pharmacy Solutions and two parent companies. He alleges the companies colluded to control drug prices and have failed to live up to promises to negotiate lower drug prices from manufacturers and deliver those savings to patients. Instead, Express Scripts created a complex 'pay to play' rebate scheme that pushes manufacturers to boost drug prices to get their medications on preferred lists. Pharmacy Benefit Manager Transparency Act Passes in Senate Committee Vote. On March 22, 2023, the Senate Committee on Commerce, Science and Transportation voted 18-9 to approve sending the bipartisan Pharmacy Benefit Manager (PBM) Transparency Act to the full Senate. The bill introduced by Democrat Commerce Committee Chair Senator Maria Cantwell of Washington and Republican Budget Committee Ranking Member Senator Chuck Grassley of Iowa in January 2023 aims to make prescription drug pricing more transparent. The Congressional Budget Office's preliminary estimates suggest that the PBM Transparency Act would save $740 million to taxpayers over the next 10 years. The legislation arises out of substantial concerns about the anti-competitive and predatory tactics that PBMs have engaged in throughout the past decade to erode the prevalence of independent pharmacies across the country. Biosimilars Are Mighty, Can Help Alleviate Drug Spend Cost Burden. Biosimilar availability also lends itself to more opportunities for substitution at the pharmacy level, like how generic products are substituted for brand name medications. However, for one biosimilar to be substituted for another without requiring physician permission, it must have an interchangeability designation from the FDA. To obtain interchangeability, most products, excluding insulins and ophthalmology products, companies are required to conduct additional clinical trials—after which pharmacists can automatically substitute them for the reference product, provided state laws allow it. Biosimilars alone are projected to have global savings of up to $150 billion by 2027.7 So, why is there still a holdup to their wider implementation? Learn More About CPBS Now! Claims Cost Transparency: Using Data to Optimize Medical Benefits Costs. Employee benefits are the second largest budget item in employee compensation, with medical benefits consuming the bulk of that cost. Yet, companies with fully insured medical plans often have limited financial transparency and control when it comes to managing these costs. Try viewing the actual, full cost for a broken ankle, and you’ll see that pricing is not so transparent. Companies that know and understand their medical & Rx claims can make decisions that will improve plan…

Pharmacogenomics is a field of study that examines how a person's genetic makeup affects their response to medication. It involves the use of genomic information to optimize drug therapy for an individual based on their unique genetic profile. Benefit consultants and brokers must recognize how pharmacogenomics benefits self-insured employers then incorporate these programs into the pharmacy benefit cost management process. The benefits of pharmacogenomics are numerous. By using genomic information to tailor drug therapy to an individual's unique genetic makeup, healthcare providers can optimize medication effectiveness while minimizing potential side effects. This approach can lead to better patient outcomes, reduced healthcare costs, and improved quality of life for patients. Keep in mind these tests aren't akin to 23andme where everyone is eligible. PGx is limited to specific genes for which testing is available. Pharmacogenomics (PGx) testing is a type of genetic testing that examines specific genes involved in drug metabolism and response. The test analyzes variations or mutations in these genes that may affect how an individual's body processes medications. The testing process typically involves a simple blood or saliva sample from the patient, which is sent to a laboratory for analysis. The laboratory then examines specific genes associated with drug metabolism and response, such as those involved in drug transport, metabolism, or receptor binding. Based on the results of the test, healthcare providers can determine how a patient's genetic makeup may impact their response to certain medications. This information can be used to adjust the dosage or select an alternative medication that is more likely to be effective or have fewer side effects based on the patient's genetic profile. In short, PGx testing eliminates wasteful spending and improves patient outcomes. Learn more about our cost management process It's important to note that pharmacogenomics testing is not appropriate for all patients or medications, and the results of the test must be interpreted in conjunction with a patient's medical history and other relevant factors. Additionally, not all insurance plans cover the cost of pharmacogenomics testing, which can be a barrier for some patients. Nonetheless, pharmacogenomics testing is a promising tool that can help healthcare providers personalize drug therapy and improve patient outcomes. For self-insured employers, pharmacogenomics can be particularly beneficial. By incorporating pharmacogenomics into their employee health programs, self-insured employers can reduce healthcare costs and improve productivity by optimizing drug therapy for their employees. Additionally, by providing personalized medication recommendations based on an individual's genetic profile, self-insured employers can demonstrate their commitment to employee wellness and enhance their reputation as a progressive employer. However, there are also challenges associated with pharmacogenomics. One of the primary challenges is the cost of genetic testing, which can be a significant barrier for some patients and employers. Additionally, there are concerns around privacy and the ethical implications of using genetic information to make medical decisions. Finally, there is a need for more research to determine the effectiveness of pharmacogenomics in various clinical settings and patient populations. In summary, pharmacogenomics has the potential to revolutionize drug…

Ohio attorney general sues pharmacy benefit managers, calling them 'gangsters,' and other notes from around the interweb: Ohio attorney general sues pharmacy benefit managers, calling them 'gangsters'. The music has stopped. Calling them "modern gangsters," Ohio Attorney General Dave Yost on Monday accused pharmacy benefit managers of illegally driving up drug prices for patients who rely on insulin and other key medications. “Medications shouldn’t cost an arm and a leg, metaphorically or literally,” Yost said in a written statement. “Insulin is just a symptom of the problem; PBMs are the disease.” Yost filed a lawsuit in Delaware County Common Pleas Court against Express Scripts, Prime Therapeutics, Ascent, Humana Pharmacy Solutions and two parent companies. He alleges the companies colluded to control drug prices and have failed to live up to promises to negotiate lower drug prices from manufacturers and deliver those savings to patients. Instead, Express Scripts created a complex 'pay to play' rebate scheme that pushes manufacturers to boost drug prices to get their medications on preferred lists. The CAA will ensure that doing the right thing is the only option. The CAA will soon begin holding employers accountable for upholding their fiduciary responsibility and exploring insurance options that lower the cost of employee health care. Word is circulating that the CAA may allow employees to sue employers if they don’t effectively manage their health care benefits. Even though the idea of employees taking legal action against their employers regarding health care benefits sounds terrible, if this interpretation is correct, it should have a positive effect on the health care industry. Should employers be worried about this new eventuality? No, not all of them. Most employers want to help their people — they just don’t fully understand that they have options. The new CAA guidelines will push employers and their brokers to explore other avenues that lower health care costs. It is simply establishing a framework to protect employees from medical debt — the leading cause of bankruptcy in the United States. Claims Cost Transparency: Using Data to Optimize Medical Benefits Costs. Employee benefits are the second largest budget item in employee compensation, with medical benefits consuming the bulk of that cost. Yet, companies with fully insured medical plans often have limited financial transparency and control when it comes to managing these costs. Try viewing the actual, full cost for a broken ankle, and you’ll see that pricing is not so transparent. Companies that know and understand their medical & Rx claims can make decisions that will improve plan utilization and reduce overall costs. Claims cost analysis allows you to drill down into the data and see what you need in your health plan to boost utilization and get your employees and their families better care. Many small and mid-size companies have fully insured plans, allowing for a fixed monthly cost. The carrier creates a pool, lumping your company with others. The carrier may determine your rate based on costs for the entire pool, meaning you’ll pay a set cost…

Study Sheds Light on Concerning New Trend in Drug Advertising and other notes from around the interweb: Top 20 GoodRx Competitors & Alternatives. GoodRx is a leading online platform that helps consumers compare prescription drug prices and offers discounts on their medications. GoodRx is the go-to source for many and is the leading online resource for free prescription drug coupons and discounts. Several of GoodRx’s competitors also provide prescription drug coupons and discounts, such as Blink Health, SingleCare, NeedyMeds, RxSaver, WellRx, Truepill, WeRx, and Optum Perks. Each of these companies offers different services and discounts, so customers research and find the best option for their needs. Here’s a look at top GoodRx competitors and alternatives and how they compare. The CAA will ensure that doing the right thing is the only option. The CAA will soon begin holding employers accountable for upholding their fiduciary responsibility and exploring insurance options that lower the cost of employee health care. Word is circulating that the CAA may allow employees to sue employers if they don’t effectively manage their health care benefits. Even though the idea of employees taking legal action against their employers regarding health care benefits sounds terrible, if this interpretation is correct, it should have a positive effect on the health care industry. Should employers be worried about this new eventuality? No, not all of them. Most employers want to help their people — they just don’t fully understand that they have options. The new CAA guidelines will push employers and their brokers to explore other avenues that lower health care costs. It is simply establishing a framework to protect employees from medical debt — the leading cause of bankruptcy in the United States. How Accumulators and Maximizers May Be Increasing Your Out-of-Pocket Drug Costs. A copay accumulator adjuster program is a type of health insurance program that affects people using biopharmaceutical patient assistance programs, which are usually provided by a drug manufacturer to help reduce the cost of taking the medication. Accumulator programs don’t allow patient assistance through the pharmaceutical industry to count toward the deductible set by the insurance company. For example, let’s say your patient assistance card has a $6,000 limit and your deductible is $6,000. After that $6,000 is covered by the patient assistance program, you still have to pay $6,000 out-of-pocket since none of it was counted toward the deductible with an accumulator adjuster program, per the Global Healthy Living Foundation (GHLF). “It started about five years ago when the pharmacy benefit management companies started introducing the accumulator program marketplace, so they convinced a lot of employers to pick it up as part of their benefit design,” says Robert Popovian, PharmD, Chief Science Policy Officer at GHLF. “But it’s not just about the accumulators. The next iteration is the maximizer program, which is a little different, but the same principle applies. Learn More About CPBS Now! Study Sheds Light on Concerning New Trend in Drug Advertising. The study, published this week in the Journal of Medical Internet…

A self-insured employer gets hit with $50 million in claims for just two members and wants the stop loss carrier and PBM to pay up. When pharmacy benefits are loosely managed, self-insured employers play right into the hands of drugmakers, rebate aggregators, non-fiduciary PBMs, and specialty pharmacies who all stand to benefit financially. Micromanaging a pharmacy benefit can nonetheless lead to very satisfied participants and improved medical outcomes. Micromanagement refers to a management style where a manager closely observes and controls the work of their employees, often involving themselves in every aspect of their work. Micromanagers tend to be excessively controlling and directive, often providing constant feedback and criticism. Advantages of micromanagement: Helps ensure that work is being done correctly and efficientlyAllows for immediate correction of mistakes or problemsProvides a high level of detail and precision in the work being doneCan be useful in situations where there is a high level of risk or complexity Disadvantages of micromanagement: Can create a negative work environment, leading to demotivated PBM employees and high turnover ratesCan lead to a lack of creativity and innovation, as PBM employees may feel discouraged from taking risks or trying new thingsCan be time-consuming and create unnecessary work for the PBMCan limit the development of employee skills and independence, as they may become overly reliant on the broker's or consultant's guidance. Overall, while micromanagement can have some benefits in certain situations, it is generally not considered an effective workplace management style as it can lead to a range of negative consequences for both employees and the organization as a whole. A more hands-off approach that focuses on trust, collaboration, and empowerment tends to be more effective in promoting a positive work culture and achieving long-term success. Taught in the Certified Pharmacy Benefits Specialist (CPBS) program However, in pharmacy benefits management, micromanagement is the rule not the exception. Loose management of the pharmacy benefit is all fine and dandy until a self-insured employer gets hit with $50 million in claims for just two members. Poor utilization management by PBMs doesn't show up in RFPs even though it is a major cost driver. The claims in question herein would have never made it through the TransparentRx clinical review process. Few PBMs in their PA workflow adhere to FDA-approved labeling, patient selection criteria, and clinical trial check points. Micromanagement of the pharmacy benefit acts as a de facto insurance policy.

The List of PBM Formulary Exclusions Grew in 2023 and other notes from around the interweb: The List of PBM Formulary Exclusions Grew in 2023. Several of the omitted products can be cheaper list-priced generics or biosimilars that the PBMs ignore in favor of branded pharmaceuticals. Critics of the practice claim that brand manufacturers' rebates are frequently to fault for this behavior, even though patients may be saddled with increased copays. Formulary exclusions were first used by major PBMs in 2011. The white bagging practice, in which payers decline to cover physician-administered pharmaceuticals unless they are delivered (white bagged) to the physicians by an authorized pharmacy, has contributed to the spread of the exclusions from the pharmacy benefit to the medical benefit side. A lot of states are taking legislative action to control white bagging. Plans can no longer refuse to pay suppliers for providing medications given by clinicians in Louisiana. Moreover, insurers are required to cover medical and pharmaceutical benefit pathways under Arkansas' anti-white bagging rule, which only pertains to hematology and oncology. The preferred pathway is up to the patient and the physician. Federal Judge Rules Cheaper Drugs Can Be Imported From Canada. In a setback to the pharmaceutical industry, a federal judge has tossed a lawsuit that sought to prevent state governments from importing medicines from Canada. And the decision is likely to embolden more states to now consider the approach as they look to lower the cost of prescription drugs. The 26-page ruling noted that to have standing, plaintiffs must prove that they have suffered an “injury in fact,” that the injury is traceable to the defendants’ conduct, and that the injury is likely to be remedied by a favorable decision. And in two distinct aspects, the plaintiffs had no standing to bring the case against the federal agencies, Kelly ruled. The DC Circuit Court has struck a blow against the pharmaceutical lobbying group PhRMA and other plaintiffs’ attempt to stop states from importing drugs from Canada. Joined alongside public health group Partnership for Safe Medicines and advocacy group Council for Affordable Health Coverage, PhRMA was rebuffed by Judge Timothy Kelly, who dismissed the civil suit due to a lack of standing. California Gov. Gavin Newsom ends $54 million Walgreens contract over abortion pill dispute. Mifepristone is a pill that when combined with another pill will end a pregnancy. The U.S. Food and Drug Administration approved the pill in 2000 for use in up to the 10th week of pregnancy. Today, more than half of all abortions in the U.S. are done by pills, according to the Guttmacher Institute, a research group that supports abortion rights. After the U.S. Supreme Court last year overturned the federal right to an abortion, more than a dozen states have restricted the use of abortion pills. But those restrictions are being challenged in court. Attorneys general in twenty states, mostly with Republican governors, have warned Walgreens and CVS they could face legal consequences if they sell abortion pills in their states.…

Drugmakers circumvent health plan sponsors' benefit designs at the switch to have expensive brand pharmaceuticals dispensed. Why don't decision-makers protest this more? By delivering eVouchers, or electronic vouchers, for pricey prescriptions at the "Switch," brand drugmakers are getting past pharmacy coverage plan designs. The switch determines which PBM, or health plan, is to receive the third-party prescription claim and is linked to the drug. In a matter of seconds, the prescription leaves the pharmacy, makes its way to the switch, and is then sent to the PBM. When the benefit design incorporates inadequate UM or utilization management restrictions, such as mandatory generic enforcement or step therapy drugmakers can use eVouchers to replace a tier 1 drug with a tier 2-4 drug or, worse yet, a non-formulary drug (see process flow diagram below). The two largest switch providers are Relay Health and Change Healthcare. Relay Health describes how its electronic voucher program is a Win-Win-Win resolution in the following way: Doctors “set aside concerns over costs”“Patients benefit from lower copays” and “increased adherence”Manufacturers benefit from increased “scripts written”, “the likelihood patients will fill and adhere to them” and “increased brand loyalty” What about the health plan sponsor, though? Despite the fact that you pay most of the expenses, you are conveniently ignored. I demonstrate in our Certified Pharmacy Benefits Specialist (CPBS) course how plan sponsors, while knowing the least about how it operates, fund the whole US prescription drug system. Simply put, they are interested in your wallet. The switch operators' eVoucher schemes have a huge budgetary impact on health plan sponsors, and that influence is only getting bigger over time. There are two ways to stop the scenario from occurring: (1) PBM inserts a provision prohibiting the action into its contract with the Switch firm(2) Benefit design maximizes the toolset for managing drug utilization, which includes mandatory generic enforcement programs, step therapy, refill to soon, and prior authorization just to name a few Number two is challenging since many plan sponsors are adamant that employees receive the medications they desire without any restrictions (i.e. step therapy). Even though I disagree, it's not my checkbook. The goal is to produce better health care outcomes at the lowest possible cost, not to save employees from the "discomfort" of managing an effective pharmacy benefit plan. In a way, pharmaceutical companies and non-fiduciary PBMs are taking advantage of HR's desire to maintain employee "happiness." Drugmakers circumvent health plan sponsors' benefit designs at the switch is a hidden cost. The decision for TransparentRx is straightforward: either you want an efficiently run pharmacy benefit program for your people or you don't. Expect to spend $1,000 for a drug when, for instance, a $100 drug would have delivered the same degree of efficacy. eVouchers are an expensive proposition for health plan sponsors but a profitable one for brand drugmakers, especially when supplemented with direct-to-consumer TV commercials for expensive brand pharmaceuticals and soft utilization management measures.

Top threats and priorities in employer-sponsored health plan benefits and other notes from around the interweb: Federal Judge Rules Cheaper Drugs Can Be Imported From Canada. In a setback to the pharmaceutical industry, a federal judge has tossed a lawsuit that sought to prevent state governments from importing medicines from Canada. And the decision is likely to embolden more states to now consider the approach as they look to lower the cost of prescription drugs. The 26-page ruling noted that to have standing, plaintiffs must prove that they have suffered an “injury in fact,” that the injury is traceable to the defendants’ conduct, and that the injury is likely to be remedied by a favorable decision. And in two distinct aspects, the plaintiffs had no standing to bring the case against the federal agencies, Kelly ruled. The DC Circuit Court has struck a blow against the pharmaceutical lobbying group PhRMA and other plaintiffs’ attempt to stop states from importing drugs from Canada. Joined alongside public health group Partnership for Safe Medicines and advocacy group Council for Affordable Health Coverage, PhRMA was rebuffed by Judge Timothy Kelly, who dismissed the civil suit due to a lack of standing. 7 Key Facts About Biosimilars. When describing biosimilars to patients, remind them that in their simplest form, medications are chemical structures, with some comprising simple, small molecules or pieces, while others are more complex. Biosimilars are made of complex chemical structures. Because biosimilars are complex medications, there are often products that treat complex conditions, such as insulin for diabetes and other biosimilars for conditions, such as multiple sclerosis or psoriasis. Many biosimilars are dispensed by specialty pharmacies, which provide medications that are typically expensive for medical conditions that are intricate and often difficult to treat. The FDA approved the first biosimilar, Zarxio (filgrastim-sndz) on March 6, 2015, for the reference product Neupogen. Zarxio was approved for all indications included on the reference product’s label, which is not the case for all biosimilars. Top Threats, Priorities in Employer-Sponsored Health Plan Benefits. Employers shared the main threats and priorities that they encounter as they try to manage employer-sponsored health plan benefits, according to a survey from the Midwest Business Group on Health (MBGH). The organization surveyed almost 60 large, self-insured employers from a broad span of industries. The survey was conducted in 2022. The top three threats to employer-sponsored healthcare coverage according to employer respondents were: high-cost pharmacy claims (94 percent), medical inflation (91 percent), and extremely expensive therapies with Food and Drug Administration approval (91 percent). Other obstacles included expensive medical claims, specialty drug spending, and high-cost patient populations. In response to these and other threats, employers highlighted certain priorities, from managing pharmacy costs to bolstering mental healthcare services. Nearly all the employers indicated that engagement in programs and benefits was a key priority for their health benefits strategies (96 percent) as well as communication around health benefits (94 percent). Over 90 percent of employers also mentioned that financial wellness, mental health, well-being, chronic…